Amarin Corp Plcuk AMRN
We take great care to ensure that the data presented and summarized in this overview for AMARIN CORP PLCUK is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMRN
View all-
Sarissa Capital Management LP Greenwich, CT24.9MShares$12.4 Million3.89% of portfolio
-
Kynam Capital Management, LP Princeton, NJ12.4MShares$6.21 Million0.64% of portfolio
-
Eversept Partners, LP New York, NY3.31MShares$1.65 Million0.16% of portfolio
-
Morgan Stanley New York, NY2.55MShares$1.27 Million0.0% of portfolio
-
Scp Investment, LP2.5MShares$1.25 Million1.16% of portfolio
-
Two Sigma Investments, LP New York, NY2.38MShares$1.19 Million0.0% of portfolio
-
Longitude (Cayman) Ltd. Grand Cayman, E92.37MShares$1.19 Million2.49% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny1.98MShares$988,0000.0% of portfolio
-
Hayek Kallen Investment Management Fairhope, AL1.02MShares$512,1570.23% of portfolio
-
Waterfront Wealth Inc.882KShares$440,9050.14% of portfolio
Latest Institutional Activity in AMRN
Top Purchases
Top Sells
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Insider Transactions at AMRN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 02
2024
|
Aaron Berg President and CEO |
BUY
Open market or private purchase
|
Direct |
160,000
+16.57%
|
$0
$0.64 P/Share
|
|
Jul 31
2024
|
Aaron Berg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,763
-1.79%
|
$0
$0.78 P/Share
|
|
Jul 31
2024
|
Aaron Berg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
23,883
+3.51%
|
-
|
|
Jul 31
2024
|
Steven B Ketchum Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,763
-1.72%
|
$0
$0.78 P/Share
|
|
Jul 31
2024
|
Steven B Ketchum Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,883
+3.38%
|
-
|
|
Jul 01
2024
|
Thomas Charles Reilly EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,209
-8.01%
|
$0
$0.69 P/Share
|
|
Jul 01
2024
|
Thomas Charles Reilly EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+13.98%
|
-
|
|
Jun 20
2024
|
Thomas Charles Reilly EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,417
-16.05%
|
$0
$0.73 P/Share
|
|
Jun 20
2024
|
Thomas Charles Reilly EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,333
+24.58%
|
-
|
|
Jan 31
2024
|
Thomas Charles Reilly EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,552
-26.26%
|
$24,552
$1.24 P/Share
|
|
Jan 31
2024
|
Thomas Charles Reilly EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,933
+32.46%
|
-
|
|
Jan 31
2024
|
Steven B Ketchum Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,187
-3.08%
|
$41,187
$1.24 P/Share
|
|
Jan 31
2024
|
Steven B Ketchum Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
79,500
+5.6%
|
-
|
|
Jan 31
2024
|
Aaron Berg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
40,822
-3.17%
|
$40,822
$1.24 P/Share
|
|
Jan 31
2024
|
Aaron Berg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
79,500
+5.81%
|
-
|
|
Jan 22
2024
|
Patrick Holt President and CEO |
BUY
Open market or private purchase
|
Direct |
14,426
+4.39%
|
$14,426
$1.09 P/Share
|
|
Jan 10
2024
|
Steven B Ketchum Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,270
-4.36%
|
$0
$0.97 P/Share
|
|
Jan 10
2024
|
Steven B Ketchum Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,500
+7.36%
|
-
|
|
Jan 10
2024
|
Aaron Berg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
28,214
-4.53%
|
$0
$0.97 P/Share
|
|
Jan 10
2024
|
Aaron Berg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,500
+7.64%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 595K shares |
|---|---|
| Payment of exercise price or tax liability | 23.5K shares |
| Open market or private purchase | 174K shares |
| Payment of exercise price or tax liability | 286K shares |
|---|---|
| Open market or private sale | 34.1K shares |